go back

Idecabtagene Vicleucel (Abecma) CAR-T Therapy

Vermont rates for HCPCS Q2055

Idecabtagene vicleucel, up to 510 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

How much rates vary

Facilitymedian $630,957 · 10th to 90th $630,957 to $630,957Professionalmedian $562,341 · 10th to 90th $562,341 to $954,993
$100K$200K$500K$1Mfacility $630,957professional $562,341

Distribution of negotiated rates across all payers (price axis is log-scale). Each curve is scaled to its own total: facility and professional rates are different services, shown together to compare where they cluster. Small sample; interpret with caution. Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier
Aetna
Setting
Professional
Modifier
Global
Typical Low
$562,341.33
Median
$562,341.33
Typical High
$954,992.59
United
Setting
Facility
Modifier
Global
Typical Low
$630,957.34
Median
$630,957.34
Typical High
$630,957.34
United
Setting
Professional
Modifier
Global
Typical Low
$60,255.96
Median
$602,559.59
Typical High
$741,310.24